Shares of AIRDOC-B (02251) fell sharply, down nearly 14% in morning trading. As of the time of writing, the stock declined 13.87% to HK$8.20, with turnover reaching HK$2.3079 million.

On the news front, the company released its interim results for 2026, reporting revenue of RMB 67.291 million for the first half of the year, a year-on-year decrease of 19.6%. The loss attributable to owners of the parent company widened to RMB 48.852 million, an increase of 2,820% compared to the same period last year.

The period's loss was primarily attributed to several factors: a decline in revenue due to the implementation of stricter agent selection policies and tightened credit terms; increased investment in research and development and clinical trials; the PBM-AI myopia prevention and control business, which is still in its expansion and cultivation phase and has yet to generate meaningful revenue contributions or economies of scale; and adverse effects from exchange rate fluctuations on the group's financial position.

Where to begin: Investors are closely monitoring whether the company can navigate these headwinds, particularly as the stricter credit policies and the ongoing ramp-up of new business segments continue to pressure near-term profitability.